Abstract: Provided are the following compound and a fluorescently labeled biological substance having this fluorescent compound. X represents CR7 or N. R1 to R7, Q1, and Q2 represent a hydrogen atom, a halogen atom, a cyano group, or a group represented by Formula (A), and adjacent substituents may form a ring structure. However, at least one of R3, R4, R7, Q1, or Q2 contains, as a hydrophilic group, at least one of a carboxy group or a salt thereof, a sulfo group or a salt thereof, a phosphono group or a salt thereof, an onio group, or a polyamino acid residue, where at least one of Q1 or Q2 represents an alkyl group.

Abstract: Provided are any one of the following fluorescent compounds and a fluorescent labeled biological substance having this fluorescent compound. X represents CR5 or N, and R1 to R7, Q1, Q2, L1, and L2 each represent a specific group. a ring ?1 and a ring ?2 are a 5- to 8-membered ring, At least one of R1 to R7, L1, L2, Q1, or Q2 has a specific hydrophilic group. However, in a case where the ring ?1 and the ring ?2 are a 6-membered ring, and L1 and L2 are an arylene group, R5 is not an aryl group substituted with a linear alkyl group having 18 or more carbon atoms. In addition to the regulation of the ring ?1, the ring ?2, L1, and L2, in a case where R5 has a substituent having a dipyrromethene boron complex structure, the dipyrromethene boron complex structure has a structure in which a dipyrromethene skeleton is coordinately bonded to a boron atom in the tridentate or tetradentate coordination.

Abstract: There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like).

Abstract: There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.

Abstract: A compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divalent group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: [Problem] Provided is a novel lubricant composition that is useful as a material of a lubricating layer of a magnetic recording medium. [Means for Resolution] The lubricant composition contains at least one kind of compound represented by the following Formula (1). In the formula, X represents a cyclic group that may be substituted, and Y represents a single bond or a linking group having a valency of 2 or more. Here, at least one of X and Y includes 1 or more polar groups such as a hydroxyl group; Z represents a linking group having a valency of 2 or more and constituted with a carbon atom (C), a fluorine atom (F), and 1 or 2 kinds of arbitrary atoms (here, a hydrogen atom is excluded); n represents a real number of 1 to 10; m represents a real number of 0 to 1; and s and t independently represent a real number of 1 or greater.

Abstract: The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R3, R4, R5, n, and X1 have the same definitions as those described in the specification), and R2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: A compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divalent group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: To provide a novel compound. It is disclosed a compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divaltn group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

Abstract: [Problem] Provided is a novel lubricant composition that is useful as a material of a lubricating layer of a magnetic recording medium. [Means for Resolution] The lubricant composition contains at least one kind of compound represented by the following Formula (1). In the formula, X represents a cyclic group that may be substituted, and Y represents a single bond or a linking group having a valency of 2 or more. Here, at least one of X and Y includes 1 or more polar groups such as a hydroxyl group; Z represents a linking group having a valency of 2 or more and constituted with a carbon atom (C), a fluorine atom (F), and 1 or 2 kinds of arbitrary atoms (here, a hydrogen atom is excluded); n represents a real number of 1 to 10; m represents a real number of 0 to 1; and s and t independently represent a real number of 1 or greater.

Abstract: To provide a novel compound. It is disclosed a compound represented by following formula (I): A-L-{D1-(E)q-D2-(B)m—Z1—R}p. In the formula, A represents a p-valent chain or cyclic residue; L represents a single bond or a divalent linking group; p represents an integer of 2 or more; D1 represents a carbonyl group (—C(?O)—) or a sulfonyl group (—S(?O)2—); D2 represents a carbonyl group (—C(?O)—), a sulfonyl group (—S(?O)2—), a carboxyl group (—C(?O)O—), a sulfonyloxyl group (—S(?O)2O—), a carbamoyl group (—C(?O)N(Alk)-) or a sulfamoyl group (—S(?O)2N(Alk)-); E represents a divaltn group; and R represents a hydrogen atom, a substituted or non-substituted C8 or longer alkyl group, a perfluoroalkyl group or a trialkylsilyl group.

Abstract: A hydrophilic film forming composition which is used for forming on the surface of a support of every sort a hydrophilic film provided with anti-fogging properties, abrasion resistance and antibacterial properties and having more favorable antifouling properties is provided. A hydrophilic member having an excellent anti-fogging, abrasion-resistant, antibacterial and antifouling surface provided with a hydrophilic film formed of the instant hydrophilic film forming composition on the surface of an appropriate support is provided. A hydrophilic film forming composition including (A) a positively charged nitrogen atom-containing compound having a Log P of not more than 2; (B) a hydrolyzable silyl group-containing hydrophilic polymer; and (C) a metal complex catalyst. A hydrophilic member including a support having the instant hydrophilic film forming composition coated thereon.